|
| 双膦酸盐预治疗减少首次应用唑来膦酸不良反应的研究 |
| Pretreatment with bisphosphonates reduces adverse effect of zoledronic acid in the first application |
| |
| DOI：10.3969/j.issn.1006.7108.2017.07.021 |
| 中文关键词: 骨质疏松 双膦酸盐 预治疗 唑来膦酸 不良反应 |
| 英文关键词:Osteoporosis Bisphosphonates Pretreatment Zoledronic acid Adverse reaction |
| 基金项目: |
|
| 摘要点击次数: 671 |
| 全文下载次数: 590 |
| 中文摘要: |
| 目的 探讨临床中减少唑来膦酸注射液（密固达）不良反应的研究。方法 选取我院骨质疏松诊疗基地首次确诊原发性骨质疏松症患者200例，符合世界卫生组织关于骨质疏松症的诊断标准。所有人组患者在口服钙和维生素D基础上随机分为3组，A组为口服阿仑膦酸钠70 mg每周一次，共3个月，3个月后静滴唑来膦酸注射液5 mg; B组为静滴伊班膦酸钠 2 mg, 3个月后静滴唑来膦酸注射液5 mg;C组为直接静滴唑来膦酸注射液5 mg,其中A、B两组为双膦酸盐预治疗组，观察3 组患者首次应用唑来膦酸注射液的不良反应情况。结果 所有入组患者中有32%首次应用唑来膦酸注射液出现不同程度的不良反应，主要表现为发热、肌肉酸痛、骨痛等症状，其中A组出现不良反应5例，B组出现不良反应7例，C组出现不良反应52例,3组均未出现腹泻、皮疹、心律失常及肝肾功能损害，将3组数据进行统计学分析，双膦酸盐预治疗组（A组和B组）首次应用唑来膦酸注射液所发生的不良反应明显比C组少，且差异具有统计学意义；A组和B组之间的不良反应差异不具有统计学意义。结论在骨质疏松症的临床治疗中，双膦酸盐预治疗能减少首次应用唑来膦酸注射液不良反应的发生，进一步提高患者依从性。 |
| 英文摘要: |
| Objective To study themethod of reducing the adverse reaction of zoledronic acid ( escitalopram) in the clinic. Methods Two hundred patients, who were diagnosed of primary osteoporosis according to WHO criteria, were included in this study. All the patients received oral calcium and vitamin D. Based on this, they were rand only divided into 3 groups. Patients in Group A received 70 mg of orally once a week for 3 months and then 5 mg of zoledronic acid injection. Patients in Group B received 2 mg of iband ronate intravenously for 3 months and then 5 mg of zoledronic acid injection. Patients in Group C received 5 mg of zoledronic acid intravenously. Groups A, B were bisphosphate salt pretreatment groups and adverse reactions of the first use of zoledronic acid were investigated. Results 32% of the patients appeared adverse reaction at the first use of zoledronic acid, including fever, muscle soreness, and bone pain. There were 5,7，and 52 cases of adverse reaction in Group A, B and C, respectively. There was no diarrhea, rash, arrhythmia, and dysfunction of liver and kidney in all the 3 groups. Statistical analysis showed that the adverse effect of zoledronic acid appeared less in groups A and B than in group C, and difference was significant. The difference of adverse reaction between group A and group B was not statistically significant. Conclusion In the clinical treatment of osteoporosis, the pretreatment with bisphosphonate can reduce the adverse reaction of the first application of zoledronic acid and improve patient compliance. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|